Drug Trial Radar · NCT07911670
Exploratory Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Nov 23, 2026
Primary completion
Mar 2029
Study completion Jun 2032
Sponsor
- Lead sponsor
- The First Affiliated Hospital of Anhui Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shanghai UniXell Biotechnology Co., Ltd
- First posted
- Nov 3, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 30 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical study is designed to explore the safety and tolerability of UX-DA003. It will also explore if UX-DA003 works to improve motor function in subjects with Parkinson's disease.
Conditions
- PARKINSON DISEASE (Disorder)
Interventions
UX-DA003Drug
UX-DA003 (Human Allogeneic iPSC-derived Midbrain Dopaminergic Progenitor cells) is used for treating patients with PD via implanting into bilateral putamina under stereotactic neurosurgery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: Within 6 months after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Anhui Medical University Recruiting
Hefei, Anhui, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.